Form 8-K - Current report:
SEC Accession No. 0001193125-25-114456
Filing Date
2025-05-07
Accepted
2025-05-07 07:36:25
Documents
15
Period of Report
2025-05-07
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d905689d8k.htm   iXBRL 8-K 47069
2 EX-99.1 d905689dex991.htm EX-99.1 28917
  Complete submission text file 0001193125-25-114456.txt   242040

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nams-20250507.xsd EX-101.SCH 3909
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nams-20250507_def.xml EX-101.DEF 12957
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nams-20250507_lab.xml EX-101.LAB 21337
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nams-20250507_pre.xml EX-101.PRE 13795
18 EXTRACTED XBRL INSTANCE DOCUMENT d905689d8k_htm.xml XML 5619
Mailing Address GOOIMEER 2-35 NARRDEN P7 1411 DC
Business Address GOOIMEER 2-35 NARRDEN P7 1411 DC 35 206 2971
NewAmsterdam Pharma Co N.V. (Filer) CIK: 0001936258 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41562 | Film No.: 25919313
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)